ANTX · Categories · Form 4

ANTX - SEC Form 4 insider transactions

AN2 Therapeutics Inc. (ANTX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ANTX

• 8d
  Principal Accounting Officer Williams Sarah Joanne sold $1,174 worth of shares (265 units at $4.43), decreasing direct ownership by 0.40% to 66,583 units (SEC Form 4) to satisfy withholding obligation

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 61d
  SEC Form 4 filed by Aziz Kabeer

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 61d
  SEC Form 4 filed by Marks Gilbert Lynn

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 61d
  SEC Form 4 filed by Martin Patricia A.

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Day Lucy

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Chanda Sanjay

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Marks Gilbert Lynn

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Aziz Kabeer

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Martin Patricia A.

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Fitzpatrick Margaret M

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Wong Stephanie

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Zakrzewski Joseph S

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Eizen Joshua M

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Spigelman Melvin K

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Readnour Robin Shane

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 79d
  SEC Form 4 filed by Easom Eric

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 97d
  Principal Accounting Officer Williams Sarah Joanne sold $347 worth of shares (327 units at $1.06), decreasing direct ownership by 0.49% to 66,848 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  Officer Eizen Joshua M was granted 50,000 shares, increasing direct ownership by 32% to 207,499 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  Chief Financial Officer Day Lucy was granted 38,000 shares, increasing direct ownership by 47% to 118,363 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  Principal Accounting Officer Williams Sarah Joanne was granted 48,375 shares, increasing direct ownership by 257% to 67,175 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  Chief Executive Officer Easom Eric was granted 112,250 shares, increasing direct ownership by 44% to 368,630 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  Chief Development Officer Chanda Sanjay was granted 38,000 shares, increasing direct ownership by 47% to 118,823 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  SEC Form 4 filed by Director Marks Gilbert Lynn

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  SEC Form 4 filed by Director Readnour Robin Shane

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  SEC Form 4 filed by Director Wong Stephanie

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  SEC Form 4 filed by Director Martin Patricia A.

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  SEC Form 4 filed by Director Spigelman Melvin K

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  SEC Form 4 filed by Director Aziz Kabeer

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  SEC Form 4 filed by Director Fitzpatrick Margaret M

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 107d
  SEC Form 4 filed by Director Zakrzewski Joseph S

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 147d
  Director Aziz Kabeer was granted 11,560 shares, increasing direct ownership by 28% to 52,479 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 147d
  Director Martin Patricia A. was granted 3,650 shares, increasing direct ownership by 28% to 16,905 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 147d
  Director Marks Gilbert Lynn was granted 11,560 shares, increasing direct ownership by 18% to 75,309 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 154d
  Chief Financial Officer Day Lucy sold $8,883 worth of shares (8,807 units at $1.01), decreasing direct ownership by 10% to 75,363 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 154d
  Chief Strategy Officer Prior Stephen David sold $6,507 worth of shares (6,462 units at $1.01), decreasing direct ownership by 10% to 59,086 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 154d
  Chief Development Officer Chanda Sanjay sold $9,332 worth of shares (9,251 units at $1.01), decreasing direct ownership by 11% to 75,823 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 154d
  Officer Eizen Joshua M sold $24,962 worth of shares (24,854 units at $1.00), decreasing direct ownership by 14% to 152,499 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 216d
  Officer Eizen Joshua M sold $3,214 worth of shares (2,819 units at $1.14), decreasing direct ownership by 2% to 177,353 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 216d
  Chief Strategy Officer Prior Stephen David sold $872 worth of shares (765 units at $1.14), decreasing direct ownership by 1% to 65,548 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 239d
  Director Martin Patricia A. was granted 3,274 shares, increasing direct ownership by 33% to 13,255 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 239d
  Director Aziz Kabeer was granted 10,367 shares, increasing direct ownership by 34% to 40,919 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 239d
  Director Marks Gilbert Lynn was granted 10,367 shares, increasing direct ownership by 19% to 63,749 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 334d
  Director Aziz Kabeer was granted 11,875 shares, increasing direct ownership by 64% to 30,552 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 334d
  Director Marks Gilbert Lynn was granted 11,875 shares, increasing direct ownership by 29% to 53,382 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 334d
  Director Martin Patricia A. was granted 3,750 shares, increasing direct ownership by 60% to 9,981 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 359d
  Large owner Leonard Braden Michael sold $218,000 worth of shares (200,000 units at $1.09) (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 376d
  Large owner Leonard Braden Michael sold $2,872,477 worth of shares (2,532,000 units at $1.13) (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 383d
  SEC Form 4 filed by Director Readnour Robin Shane

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 383d
  SEC Form 4 filed by Director Martin Patricia A.

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 383d
  SEC Form 4 filed by Director Fitzpatrick Margaret M

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 383d
  SEC Form 4 filed by Director Zakrzewski Joseph S

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 383d
  SEC Form 4 filed by Director Spigelman Melvin K

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 383d
  SEC Form 4 filed by Director Wong Stephanie

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 383d
  SEC Form 4 filed by Director Marks Gilbert Lynn

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 383d
  SEC Form 4 filed by Director Aziz Kabeer

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 425d
  Director Zakrzewski Joseph S was granted 10,523 shares, increasing direct ownership by 8% to 145,538 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 425d
  Director Aziz Kabeer was granted 9,705 shares, increasing direct ownership by 108% to 18,677 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 425d
  Director Marks Gilbert Lynn was granted 9,705 shares, increasing direct ownership by 31% to 41,507 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 467d
  Chief Development Officer Chanda Sanjay was granted 50,250 shares, increasing direct ownership by 168% to 80,074 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
• 467d
  Chief Financial Officer Day Lucy was granted 46,500 shares, increasing direct ownership by 142% to 79,170 units (SEC Form 4)

  4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

Other ANTX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends